Study Information for: "Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer" - Be Involved - CepEsperu Baptist Health

What we are studying

The purpose of this study is to compare the combination of carboplatin, paclitaxel and veliparib to carboplatin, paclitaxel, and placebo followed by continued therapy with either veliparib or placebo to determine if it slows the progression of your cancer. A BRCA gene test will be required for your participation to further assess treatment response. You will need to have this sample collected, even if you have already been tested for it previously.

Who is Eligible

Genders:
- Women
Races:
- White
- African American
- Asian
- American Indian or Alaska Native
- Native Hawaiian or Pacific Islander
- Other
Hispanic or Latino
Ages 18+

Eligibility Criteria

Previously untreated Stages III or IV High-grade serous epithelial ovarian fallopian tube or primary peritoneal cancer

What is involved

Arm 1: Carboplatin/paclitaxel plus placebo for six 21-day cycles followed by placebo maintenance therapy for 30 additional 21-day cycles; Arm 2: Carboplatin/paclitaxel plus veliparib for six 21-day cycles followed by placebo maintenance therapy for 30 additional 21-day cycles; Arm 3: Carboplatin/paclitaxel plus veliparib for six 21-day cycles followed by veliparib BID maintenance therapy for 30 additional 21-day cycles.